Humulin R U-500 Kwikpen (Insulin Regular, Human) — Medicare Part D spending
Eli Lilly & Co. · Rank #184 by total Part D spend · CMS data year 2023
Medicare Part D spent $263,635,305 on Humulin R U-500 Kwikpen (Insulin Regular, Human) in 2023, the #184 drug by total Part D spending out of 3,598 drugs. That worked out to about $97.23 per dosage unit, $1,830 per claim and $10,111 per beneficiary, across 144,089 claims for 26,073 beneficiaries. Average spending per dosage unit rose +1.0% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Humulin R U-500 Kwikpen (Insulin Regular, Human) spending at a glance (2023)
| Metric | Humulin R U-500 Kwikpen (Insulin Regular, Human) |
|---|---|
| Total Part D spending (2023) | $263,635,305 |
| Total spending (2022) | $253,650,899 |
| Year-over-year change in total spending | +3.9% |
| Average spending per dosage unit (2023) | $97.23 |
| Change in spend per dosage unit (YoY) | +1.0% |
| Avg annual change per dosage unit (2019-2023 CAGR) | +0.9% |
| Average spending per claim (2023) | $1,830 |
| Average spending per beneficiary (2023) | $10,111 |
| Total claims (2023) | 144,089 |
| Beneficiaries (2023) | 26,073 |
| Total dosage units (2023) | 2,711,410 |
| Manufacturer(s) | Eli Lilly & Co. |
| National rank by total spend (of 3,598 drugs) | #184 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
2022 vs 2023
| Metric | 2022 | 2023 | Change |
|---|---|---|---|
| Total spending | $253,650,899 | $263,635,305 | +3.9% |
| Avg spend per dosage unit | $96.31 | $97.23 | +1.0% |
| Avg spend per claim | $1,793 | $1,830 | — |
| Avg spend per beneficiary | $10,097 | $10,111 | — |
| Total claims | 141,482 | 144,089 | — |
| Beneficiaries | 25,121 | 26,073 | — |
How Humulin R U-500 Kwikpen compares with nearby drugs
Drugs with total Part D spending closest to Humulin R U-500 Kwikpen (Insulin Regular, Human):
| Drug (rank) | Total spend 2023 | Per dosage unit | Per-unit YoY |
|---|---|---|---|
| Humulin R U-500 Kwikpen (Insulin Regular, Human) (this drug, #184) | $263,635,305 | $97.23 | +1.0% |
| Rytary (Carbidopa/Levodopa) (#182) | $266,869,488 | $4.49 | +8.7% |
| Gammaplex (Immun Glob G(IgG)/Gly/IgA 0-50) (#183) | $265,296,669 | $20.41 | +7.6% |
| Oxycodone-Acetaminophen (Oxycodone HCl/Acetaminophen) (#185) | $263,023,627 | $0.37 | +5.5% |
| Nucala (Mepolizumab) (#186) | $260,986,344 | $3,769.30 | +8.8% |
| Strensiq (Asfotase Alfa) (#187) | $258,940,106 | $6,180.92 | -0.9% |
Frequently asked questions
How much does Medicare Part D spend on Humulin R U-500 Kwikpen?
Medicare Part D spent $263,635,305 on Humulin R U-500 Kwikpen (Insulin Regular, Human) in 2023 (the latest CMS data year), across 144,089 claims for 26,073 beneficiaries. That ranks #184 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.
What is the average spending per dosage unit for Humulin R U-500 Kwikpen?
In 2023, the weighted average Medicare Part D spending per dosage unit for Humulin R U-500 Kwikpen (Insulin Regular, Human) was $97.23. Compared with 2022 it rose +1.0%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.
Who makes Humulin R U-500 Kwikpen?
CMS attributes Humulin R U-500 Kwikpen (Insulin Regular, Human) to Eli Lilly & Co. in the 2023 Part D spending file. Average spending per claim was $1,830 and per beneficiary $10,111.
Is the Humulin R U-500 Kwikpen figure the price I pay?
No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.
Keep exploring
Source & what this means
Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-20